Annual Total Liabilities
$588.10 M
-$41.63 M-6.61%
December 31, 2023
Summary
- As of February 12, 2025, TVTX annual total liabilities is $588.10 million, with the most recent change of -$41.63 million (-6.61%) on December 31, 2023.
- During the last 3 years, TVTX annual total liabilities has risen by +$191.88 million (+48.43%).
- TVTX annual total liabilities is now -6.61% below its all-time high of $629.73 million, reached on December 31, 2022.
Performance
TVTX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$534.86 M
-$1.11 M-0.21%
September 30, 2024
Summary
- As of February 12, 2025, TVTX quarterly total liabilities is $534.86 million, with the most recent change of -$1.11 million (-0.21%) on September 30, 2024.
- Over the past year, TVTX quarterly total liabilities has dropped by -$53.24 million (-9.05%).
- TVTX quarterly total liabilities is now -15.07% below its all-time high of $629.73 million, reached on December 31, 2022.
Performance
TVTX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
TVTX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.6% | -9.1% |
| 3 y3 years | +48.4% | -15.1% |
| 5 y5 years | +50.5% | -15.1% |
TVTX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -6.6% | +23.9% | -15.1% | +12.7% |
| 5 y | 5-year | -6.6% | +53.3% | -15.1% | +54.0% |
| alltime | all time | -6.6% | >+9999.0% | -15.1% | >+9999.0% |
Travere Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $534.86 M(-0.2%) |
| Jun 2024 | - | $535.97 M(-9.1%) |
| Mar 2024 | - | $589.48 M(+0.2%) |
| Dec 2023 | $588.10 M(-6.6%) | $588.10 M(+6.3%) |
| Sep 2023 | - | $553.08 M(-10.8%) |
| Jun 2023 | - | $619.94 M(+0.1%) |
| Mar 2023 | - | $619.09 M(-1.7%) |
| Dec 2022 | $629.73 M(+32.7%) | $629.73 M(+0.7%) |
| Sep 2022 | - | $625.54 M(+0.4%) |
| Jun 2022 | - | $622.78 M(+0.4%) |
| Mar 2022 | - | $620.26 M(+30.7%) |
| Dec 2021 | $474.52 M(+19.8%) | $474.52 M(+1.5%) |
| Sep 2021 | - | $467.70 M(+12.8%) |
| Jun 2021 | - | $414.46 M(+3.3%) |
| Mar 2021 | - | $401.36 M(+1.3%) |
| Dec 2020 | $396.23 M(+3.3%) | $396.23 M(+1.4%) |
| Sep 2020 | - | $390.81 M(+8.5%) |
| Jun 2020 | - | $360.05 M(+3.7%) |
| Mar 2020 | - | $347.31 M(-9.5%) |
| Dec 2019 | $383.60 M(-1.9%) | $383.60 M(+4.3%) |
| Sep 2019 | - | $367.86 M(-0.7%) |
| Jun 2019 | - | $370.49 M(-3.0%) |
| Mar 2019 | - | $381.96 M(-2.3%) |
| Dec 2018 | $390.91 M(+72.0%) | $390.91 M(-1.6%) |
| Sep 2018 | - | $397.12 M(+95.5%) |
| Jun 2018 | - | $203.16 M(+0.9%) |
| Mar 2018 | - | $201.32 M(-11.4%) |
| Dec 2017 | $227.21 M | $227.21 M(+5.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $215.99 M(+2.2%) |
| Jun 2017 | - | $211.30 M(+0.9%) |
| Mar 2017 | - | $209.45 M(-3.7%) |
| Dec 2016 | $217.51 M(+2.5%) | $217.51 M(-3.3%) |
| Sep 2016 | - | $224.82 M(+2.4%) |
| Jun 2016 | - | $219.60 M(+16.9%) |
| Mar 2016 | - | $187.87 M(-11.5%) |
| Dec 2015 | $212.29 M(+22.9%) | $212.29 M(-3.8%) |
| Sep 2015 | - | $220.62 M(-19.6%) |
| Jun 2015 | - | $274.36 M(+10.9%) |
| Mar 2015 | - | $247.42 M(+43.2%) |
| Dec 2014 | $172.72 M(+330.0%) | $172.72 M(+10.6%) |
| Sep 2014 | - | $156.12 M(+1.1%) |
| Jun 2014 | - | $154.47 M(+19.3%) |
| Mar 2014 | - | $129.44 M(+222.3%) |
| Dec 2013 | $40.17 M(+592.6%) | $40.17 M(+47.8%) |
| Sep 2013 | - | $27.17 M(+144.1%) |
| Jun 2013 | - | $11.13 M(+36.2%) |
| Mar 2013 | - | $8.17 M(>+9900.0%) |
| Dec 2012 | $5.80 M(+8555.4%) | - |
| Nov 2012 | - | $68.70 K(+1.0%) |
| Aug 2012 | - | $68.00 K(+0.7%) |
| May 2012 | - | $67.50 K(+0.7%) |
| Feb 2012 | - | $67.00 K(+2.0%) |
| Feb 2012 | $67.00 K(+4.4%) | - |
| Nov 2011 | - | $65.70 K(+0.8%) |
| Aug 2011 | - | $65.20 K(+1.6%) |
| Feb 2011 | $64.20 K | $64.20 K |
FAQ
- What is Travere Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Travere Therapeutics?
- What is Travere Therapeutics annual total liabilities year-on-year change?
- What is Travere Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Travere Therapeutics?
- What is Travere Therapeutics quarterly total liabilities year-on-year change?
What is Travere Therapeutics annual total liabilities?
The current annual total liabilities of TVTX is $588.10 M
What is the all time high annual total liabilities for Travere Therapeutics?
Travere Therapeutics all-time high annual total liabilities is $629.73 M
What is Travere Therapeutics annual total liabilities year-on-year change?
Over the past year, TVTX annual total liabilities has changed by -$41.63 M (-6.61%)
What is Travere Therapeutics quarterly total liabilities?
The current quarterly total liabilities of TVTX is $534.86 M
What is the all time high quarterly total liabilities for Travere Therapeutics?
Travere Therapeutics all-time high quarterly total liabilities is $629.73 M
What is Travere Therapeutics quarterly total liabilities year-on-year change?
Over the past year, TVTX quarterly total liabilities has changed by -$53.24 M (-9.05%)